8-K: Phathom Q3 Revenue Jumps 25%, Nears Profitability

Phathom Pharmaceuticals reported strong third-quarter 2025 financial results, with net revenues up 25% quarter-over-quarter and reduced cash usage, advancing towards operating profitability in 2026.

Summary

• Phathom Pharmaceuticals reported third-quarter 2025 financial results, showing significant growth in VOQUEZNA prescriptions and net revenues.
• Net revenues for Q3 2025 were $49.5 million, a 25% increase quarter-over-quarter and up from $16.4 million in Q3 2024.
• VOQUEZNA prescriptions filled increased by 28% from Q2 2025, totaling over 790,000 prescriptions to date as of October 17, 2025.
• Operating expenses decreased sequentially by 43% from Q2 2025, with Q3 2025 operating expenses at $58.6 million, down from $94.4 million in Q2 2025.
• Net loss for Q3 2025 was $30.0 million, a significant improvement from $85.6 million in Q3 2024.
• Cash and cash equivalents stood at $135.2 million as of September 30, 2025, with net cash usage improving by 77% quarter-over-quarter to approximately $14 million.
• The company updated its full-year 2025 revenue guidance to $170 million to $175 million and expects to achieve operating profitability in 2026 without additional equity financing.
• Initiated a Phase 2 trial for VOQUEZNA in Eosinophilic Esophagitis (EoE) in October 2025, with topline results anticipated in 2027.
• Strengthened leadership team with new Chief Financial and Business Officer and Senior Vice President, Marketing and Analytics.

Sentiment

Score: 8

Explanation: The company demonstrated strong commercial execution with significant revenue growth, substantial reduction in operating expenses and cash burn, and an improved net loss. The updated revenue guidance and expectation of achieving operating profitability in 2026 without further equity financing are highly positive indicators. While still operating at a loss, the trajectory is clearly positive and better than expected.

Positives

• Net revenues for Q3 2025 increased to $49.5 million, up 25% quarter-over-quarter and 202% year-over-year from $16.4 million in Q3 2024.
• VOQUEZNA prescriptions filled increased 28% quarter-over-quarter in Q3 2025, reaching approximately 221,000 prescriptions.
• Total VOQUEZNA prescriptions filled to date exceeded 790,000 as of October 17, 2025.
• Operating expenses decreased significantly, with Q3 2025 operating expenses at $58.6 million, down 43% from $94.4 million in Q2 2025.
• Net loss improved substantially to $30.0 million in Q3 2025, compared to $85.6 million in Q3 2024.
• Non-GAAP adjusted net loss improved to $11.2 million in Q3 2025, compared to $67.9 million in Q3 2024.
• Net cash usage improved by 77% quarter-over-quarter, from approximately $63 million in Q2 2025 to $14 million in Q3 2025.
• The company expects to achieve operating profitability in 2026, excluding stock-based compensation, without the need for additional equity financing.
• Updated full-year 2025 revenue guidance to $170 million to $175 million, indicating continued strong performance.
• Initiated Phase 2 pHalcon-EoE-201 trial for VOQUEZNA in Eosinophilic Esophagitis (EoE).
• Published additional positive data from the Phase 3 pHalcon-NERD-301 trial showing VOQUEZNA improved nocturnal GERD symptoms.
• Strengthened leadership team with key hires in finance and marketing.
• Expects New Chemical Entity (NCE) exclusivity for VOQUEZNA 10 mg and 20 mg tablets through May 2032, with generic entry unlikely before 2033.

Negatives

• Despite significant improvements, the company still reported a net loss of $30.0 million for Q3 2025.
• Cash and cash equivalents decreased from $297.263 million as of December 31, 2024, to $135.156 million as of September 30, 2025.
• Total stockholders' deficit increased from $(253.580) million as of December 31, 2024, to $(422.534) million as of September 30, 2025.
• Stock-based compensation expense increased to $9.3 million in Q3 2025 from $5.6 million in Q3 2024.

Risks

• Inability to successfully commercialize VOQUEZNA or achieve expected revenue and growth levels.
• Market opportunity for VOQUEZNA may be significantly smaller than expectations.
• Market acceptance for VOQUEZNA from healthcare professionals, patients, and payors may be significantly lower than anticipated.
• Potential for coverage, reimbursement, market access, or other issues impacting commercialization efforts.
• Unmet need for new treatment options in GERD may not be as high as anticipated.
• Estimates of patient numbers and potential market size may not be accurate.
• Resource allocation decisions may not lead to expected results.
• Failure to seek, achieve, or maintain expected patent and regulatory exclusivity, leading to earlier generic competition.
• Negative impact from the launch of other competitive products.
• Adverse impact due to dependence on third parties for commercialization, manufacturing, research, and testing.
• Negative impact from regulatory developments or governmental actions, including healthcare reform.
• Unexpected adverse side effects or inadequate efficacy of VOQUEZNA, potentially limiting market acceptance, development, or regulatory approvals, or resulting in recalls, withdrawals, or product liability claims.
• Inability to obtain and maintain intellectual property protection.
• Risk of Takeda terminating the license agreement for vonoprazan if the company breaches it.
• Issues with ongoing or planned clinical trials, including slower than expected enrollment affecting timing or success.
• Negative or mixed results from ongoing or future clinical trials impacting business, goals, or future opportunities.
• Operating expenses may be higher than anticipated due to unforeseen activities or unexpected expenses, including litigation.
• May not achieve profitability on expected timelines or at all.
• May not have sufficient cash to fund operations or meet obligations in the future.
• May need to or decide to raise additional capital, potentially not on acceptable terms.

Future Outlook

Phathom Pharmaceuticals updated its full-year 2025 revenue guidance to $170 million to $175 million. The company expects to achieve operating profitability in 2026, excluding stock-based compensation, and believes its current cash resources will be sufficient to fund operations until then without the need for additional equity financing. Topline results from the Phase 2 pHalcon-EoE-201 trial for VOQUEZNA in Eosinophilic Esophagitis are anticipated in 2027. The company believes New Chemical Entity (NCE) exclusivity for VOQUEZNA 10 mg and 20 mg tablets will extend through May 2032, making generic entry unlikely before 2033.

Management Comments

• "Our performance this quarter reinforces our belief in the strength of our GI-focused call strategy and reflects disciplined execution across the business." Steve Basta, President and Chief Executive Officer.
• "Momentum for VOQUEZNA tablets continues to build as we deepen engagement with gastroenterologists." Steve Basta, President and Chief Executive Officer.
• "In the third quarter we grew revenues, reduced expenses, and reduced cash usage in line with our previously communicated plan." Steve Basta, President and Chief Executive Officer.
• "With strong commercial performance this quarter, continued expense discipline, and an experienced leadership team in place, we are advancing toward our goal of becoming a leader in GI." Steve Basta, President and Chief Executive Officer.

Industry Context

The biopharmaceutical industry, particularly in gastrointestinal diseases, is highly competitive. Phathom's focus on deepening engagement with gastroenterologists for VOQUEZNA, a first-in-class potassium-competitive acid blocker (PCAB), positions it against established proton pump inhibitors (PPIs) and other emerging treatments for GERD and H. pylori. The initiation of a Phase 2 trial for Eosinophilic Esophagitis (EoE) indicates an expansion into new indications within the GI space, a common strategy for companies seeking to maximize drug lifecycle value and address unmet medical needs. The strengthening of the leadership team with experienced biopharmaceutical executives suggests a strategic push for commercial scaling and market penetration, aligning with broader industry trends of optimizing commercial operations for specialized therapies.

Comparison to Industry Standards

• The 25% quarter-over-quarter revenue growth for VOQUEZNA is strong, especially for a specialized GI product, and compares favorably to many established pharmaceutical products that typically see slower, more mature growth rates.
• The 28% quarter-over-quarter increase in VOQUEZNA prescriptions filled demonstrates robust market uptake, potentially outperforming the average growth for new drug launches in competitive therapeutic areas.
• The 77% improvement in net cash usage quarter-over-quarter is a significant operational efficiency gain, indicating strong cost control measures that could set a benchmark for other commercial-stage biopharmaceutical companies aiming for profitability.
• The expectation of achieving operating profitability in 2026 without additional equity financing is a strong indicator of financial discipline and commercial success, distinguishing Phathom from many development-stage or early commercial-stage biotechs that frequently require ongoing capital raises.
• The appointment of Sanjeev Narula, who previously served as CFO at Intra-Cellular Therapies through its $14.6 billion acquisition by Johnson & Johnson, brings a level of M&A and scaling experience that is highly valued in the biopharmaceutical sector and comparable to leadership teams at larger, more established companies.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, reduced expenses, improved cash usage, updated positive revenue guidance, and the expectation of achieving operating profitability without further equity dilution. The strengthening of the leadership team and pipeline expansion also adds value.
• Employees: Potential positive impact from a strengthening company, though sales force realignment and cost reductions could imply some internal restructuring or efficiency drives. New leadership hires indicate strategic growth.
• Customers (Patients): Positive impact from continued commercialization and availability of VOQUEZNA for GERD and H. pylori, and potential future treatment for EoE.
• Healthcare Professionals (Gastroenterologists): Increased engagement and focus from the sales force, potentially leading to better support and information regarding VOQUEZNA.
• Creditors: Positive impact from improved financial performance and a clear path to profitability, reducing credit risk.

Next Steps

• Continue deepening sales call engagement with gastroenterologists.
• Treat the first patient in the Phase 2 pHalcon-EoE-201 trial in the fourth quarter of 2025.
• Anticipate topline results from the Phase 2 pHalcon-EoE-201 trial in 2027.
• Host a conference call and webcast on October 30, 2025, at 8:00 a.m. EDT to discuss Q3 2025 financial results and business highlights.
• Achieve operating profitability in 2026.
• Maintain New Chemical Entity (NCE) exclusivity for VOQUEZNA 10 mg and 20 mg tablets through May 2032.

Key Dates

Recommendation

The filing indicates a strong positive trajectory for Phathom Pharmaceuticals. The significant quarter-over-quarter revenue growth (25%), substantial reduction in operating expenses (43%), and a 77% improvement in net cash usage demonstrate effective commercial execution and financial discipline. The updated full-year revenue guidance of $170-$175 million and the explicit expectation to achieve operating profitability in 2026 without additional equity financing are key catalysts. The expansion into Eosinophilic Esophagitis with a Phase 2 trial and the strengthening of the leadership team further support long-term growth potential. These factors collectively suggest that the company is executing well on its strategy and is on a clear path to improved financial health and market leadership in GI, making it an attractive investment.

Keywords

Phathom Pharmaceuticals, PHAT, VOQUEZNA, GERD, Non-Erosive GERD, Erosive GERD, H. pylori, Eosinophilic Esophagitis, EoE, Q3 2025, financial results, biopharmaceutical, gastrointestinal diseases, PCAB, vonoprazan, revenue, operating expenses, net loss, cash, clinical trials, NCE exclusivity, corporate governance